Beijing, August 17
China’s vaccine specialist CanSino Biologics Inc has received a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing paperwork from the nation’s mental property regulator.
It is the primary COVID-19 vaccine patent granted by China, state-owned newspaper People’s Daily reported on Sunday.
The paper cited paperwork printed by China’s National Intellectual Property Administration saying that the patent was issued on August 11.
Saudi Arabia stated this month it plans to start Phase III medical trials for the CanSino vaccine. CanSino has stated additionally it is in talks with Russia, Brazil and Chile to launch Phase III trials in these nations.
CanSino’s Hong Kong shares rose round 14 per cent in Monday’s morning session. Its Shanghai shares rose by 6.6 per cent as of noon. Reuters